{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T20:49:57Z","timestamp":1787690997704,"version":"build-2784847793"},"reference-count":29,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"BL&H Company","award":["06-2018-085"],"award-info":[{"award-number":["06-2018-085"]}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Joint Bone Spine"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1016\/j.jbspin.2020.07.006","type":"journal-article","created":{"date-parts":[[2020,7,22]],"date-time":"2020-07-22T21:19:50Z","timestamp":1595452790000},"page":"105057","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Risk factors associated with initiation of a biologic disease modifying anti-rheumatic drug in patients with rheumatoid arthritis: A nested case-control study on 34,925 patients"],"prefix":"10.1016","volume":"88","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6813-4182","authenticated-orcid":false,"given":"Eun Hye","family":"Park","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Shin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"You-Jung","family":"Ha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun Jong","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eun Bong","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yeong Wook","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9697-1159","authenticated-orcid":false,"given":"Eun Ha","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jbspin.2020.07.006_bib0150","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1038\/nrrheum.2009.182","article-title":"Treatment of rheumatoid arthritis: state of the art 2009","volume":"5","author":"van Vollenhoven","year":"2009","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.jbspin.2020.07.006_bib0155","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1097\/BOR.0000000000000496","article-title":"Recent advances in the treatment of rheumatoid arthritis","volume":"30","author":"Mahajan","year":"2018","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.jbspin.2020.07.006_bib0160","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1136\/annrheumdis-2016-210713","article-title":"Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2016 update of the EULAR recommendations for the management of rheumatoid arthritis","volume":"76","author":"Nam","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2020.07.006_bib0165","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1136\/annrheumdis-2016-210715","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update","volume":"76","author":"Smolen","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2020.07.006_bib0170","doi-asserted-by":"crossref","first-page":"2824","DOI":"10.1002\/art.34498","article-title":"A randomized comparative effectiveness study of oral triple therapy versus etanercept plus methotrexate in early aggressive rheumatoid arthritis: the treatment of Early Aggressive Rheumatoid Arthritis Trial","volume":"64","author":"Moreland","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2020.07.006_bib0175","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1056\/NEJMoa1303006","article-title":"Therapies for active rheumatoid arthritis after methotrexate failure","volume":"369","author":"O\u2019Dell","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jbspin.2020.07.006_bib0180","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1136\/annrheumdis-2013-203819","article-title":"Variations in criteria regulating treatment with reimbursed biologic DMARDs across European countries. Are differences related to country's wealth?","volume":"73","author":"Putrik","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2020.07.006_bib0185","first-page":"401","article-title":"Factors associated with the initiation of biologic disease-modifying antirheumatic drugs in Texas Medicaid patients with rheumatoid arthritis","volume":"21","author":"Kim","year":"2015","journal-title":"J Manag Care Spec Pharm"},{"key":"10.1016\/j.jbspin.2020.07.006_bib0190","first-page":"1110","article-title":"Predictors of treatment initiation with tumor necrosis factor-alpha inhibitors in patients with rheumatoid arthritis","volume":"20","author":"Desai","year":"2014","journal-title":"J Manag Care Spec Pharm"},{"key":"10.1016\/j.jbspin.2020.07.006_bib0195","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1001\/jama.2018.16501","article-title":"Association of Blood Pressure Classification in Korean Young Adults According to the 2017 American College of Cardiology\/American Heart Association Guidelines With Subsequent Cardiovascular Disease Events","volume":"320","author":"Son","year":"2018","journal-title":"JAMA"},{"key":"10.1016\/j.jbspin.2020.07.006_bib0200","doi-asserted-by":"crossref","first-page":"R32","DOI":"10.1186\/ar3260","article-title":"Validation of rheumatoid arthritis diagnoses in health care utilization data","volume":"13","author":"Kim","year":"2011","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.jbspin.2020.07.006_bib0205","doi-asserted-by":"crossref","first-page":"2985","DOI":"10.1007\/s00296-013-2833-x","article-title":"Development of an algorithm for identifying rheumatoid arthritis in the Korean National Health Insurance claims database","volume":"33","author":"Cho","year":"2013","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.jbspin.2020.07.006_bib0210","first-page":"1","article-title":"Early rheumatoid arthritis \u2013 is there a window of opportunity?","volume":"80","author":"Cush","year":"2007","journal-title":"J Rheumatol Suppl"},{"key":"10.1016\/j.jbspin.2020.07.006_bib0215","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1016\/j.jclinepi.2004.03.012","article-title":"New ICD-10 version of the Charlson comorbidity index predicted in-hospital mortality","volume":"57","author":"Sundararajan","year":"2004","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.jbspin.2020.07.006_bib0220","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1136\/annrheumdis-2013-204573","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update","volume":"73","author":"Smolen","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2020.07.006_bib0225","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1093\/rheumatology\/ker356","article-title":"Effectiveness of sulfasalazine and methotrexate in 1102 DMARD-naive patients with early RA","volume":"51","author":"Lie","year":"2012","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jbspin.2020.07.006_bib0230","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1136\/ard.60.10.913","article-title":"Treatment of active rheumatoid arthritis with leflunomide: two year follow up of a double blind, placebo controlled trial versus sulfasalazine","volume":"60","author":"Scott","year":"2001","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2020.07.006_bib0235","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1097\/BOR.0b013e328344f2e4","article-title":"Methotrexate versus leflunomide in rheumatoid arthritis: what is new in 2011?","volume":"23","author":"Singer","year":"2011","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.jbspin.2020.07.006_bib0240","doi-asserted-by":"crossref","first-page":"836","DOI":"10.3109\/14397595.2016.1160969","article-title":"Effectiveness of tacrolimus in comparison with methotrexate or biologics in propensity score-matched patients with rheumatoid arthritis","volume":"26","author":"Nakajima","year":"2016","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.jbspin.2020.07.006_bib0245","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1002\/art.10427","article-title":"Efficacy of tacrolimus in rheumatoid arthritis patients who have been treated unsuccessfully with methotrexate: a six-month, double-blind, randomized, dose-ranging study","volume":"46","author":"Furst","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2020.07.006_bib0250","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s12016-018-8672-5","article-title":"Sex and management of rheumatoid arthritis","volume":"56","author":"Favalli","year":"2019","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.jbspin.2020.07.006_bib0255","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1016\/j.socscimed.2008.05.034","article-title":"Explaining gender differences in ill-health in South Korea: the roles of socio-structural, psychosocial, and behavioral factors","volume":"67","author":"Chun","year":"2008","journal-title":"Soc Sci Med"},{"key":"10.1016\/j.jbspin.2020.07.006_bib0260","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1161\/01.CIR.0000124490.27666.B2","article-title":"Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL)","volume":"109","author":"Mann","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.jbspin.2020.07.006_bib0265","doi-asserted-by":"crossref","first-page":"3133","DOI":"10.1161\/01.CIR.0000077913.60364.D2","volume":"107","author":"Chung","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.jbspin.2020.07.006_bib0270","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1136\/ard.2009.125476","article-title":"Risk of diabetes among patients with rheumatoid arthritis, psoriatic arthritis and psoriasis","volume":"69","author":"Solomon","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2020.07.006_bib0275","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1136\/ard.54.1.45","article-title":"Hip involvement in early rheumatoid arthritis","volume":"54","author":"Eberhardt","year":"1995","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2020.07.006_bib0280","doi-asserted-by":"crossref","first-page":"6930297","DOI":"10.1155\/2018\/6930297","article-title":"Lung involvements in rheumatic diseases: update on the epidemiology, pathogenesis, clinical features, and treatment","volume":"2018","author":"Ha","year":"2018","journal-title":"Biomed Res Int"},{"key":"10.1016\/j.jbspin.2020.07.006_bib0285","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/art.39480","article-title":"2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis","volume":"68","author":"Singh","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.jbspin.2020.07.006_bib0290","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1093\/qjmed\/hcp165","article-title":"Autoantibodies in rheumatoid arthritis: rheumatoid factors and anticitrullinated protein antibodies","volume":"103","author":"Song","year":"2010","journal-title":"QJM"}],"container-title":["Joint Bone Spine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1297319X20301421?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1297319X20301421?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T16:27:32Z","timestamp":1761150452000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1297319X20301421"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["S1297319X20301421"],"URL":"https:\/\/doi.org\/10.1016\/j.jbspin.2020.07.006","relation":{},"ISSN":["1297-319X"],"issn-type":[{"value":"1297-319X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Risk factors associated with initiation of a biologic disease modifying anti-rheumatic drug in patients with rheumatoid arthritis: A nested case-control study on 34,925 patients","name":"articletitle","label":"Article Title"},{"value":"Joint Bone Spine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jbspin.2020.07.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Soci\u00e9t\u00e9 fran\u00e7aise de rhumatologie. Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"105057"}}